Future medicinal chemistry最新文献

Advances of deep Neural Networks (DNNs) in the development of peptide drugs. 深度神经网络（DNN）在多肽药物开发中的应用进展。

IF 3.2 4区医学

Future medicinal chemistry Pub Date : 2025-02-12 DOI: 10.1080/17568919.2025.2463319

Yuzhen Niu, Pingyang Qin, Ping Lin

{"title":"Advances of deep Neural Networks (DNNs) in the development of peptide drugs.","authors":"Yuzhen Niu, Pingyang Qin, Ping Lin","doi":"10.1080/17568919.2025.2463319","DOIUrl":"https://doi.org/10.1080/17568919.2025.2463319","url":null,"abstract":"Peptides are able to bind to difficult disease targets with high potency and specificity, providing great opportunities to meet unmet medical requirements. Nevertheless, the unique features of peptides, such as their small size, high structural flexibility, and scarce data availability, bring extra challenges to the design process. Firstly, this review sums up the application of peptide drugs in treating diseases. Then, the review probes into the advantages of Deep Neural Networks (DNNs) in predicting and designing peptide structures. DNNs have demonstrated remarkable capabilities in structural prediction, enabling accurate three-dimensional modeling of peptide drugs through models like AlphaFold and its successors. Finally, the review deliberates on the challenges and coping strategies of DNNs in the development of peptide drugs, along with future research directions. Future research directions focus on further improving the accuracy and efficiency of DNN-based peptide drug design, exploring novel applications of peptide drugs, and accelerating their clinical translation. With continuous advancements in technology and data accumulation, DNNs are poised to play an increasingly crucial role in the field of peptide drug development.","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"1-15"},"PeriodicalIF":3.2,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A call to develop tramadol enantiomer for overcoming the tramadol crisis by reducing addiction.

IF 3.2 4区医学

Future medicinal chemistry Pub Date : 2025-02-11 DOI: 10.1080/17568919.2025.2463314

Ilaria D'Acquarica, Israel Agranat

引用次数: 0

Design, synthesis and biological evaluation of non-glucosidal based 1,3,4-thiadiazoles as SGLT-2 inhibitors.

IF 3.2 4区医学

Future medicinal chemistry Pub Date : 2025-02-11 DOI: 10.1080/17568919.2025.2463869

Shivani Sharma, Shubham Kumar, Jeena Gupta, Amit Mittal, Navneet Khurana

{"title":"Design, synthesis and biological evaluation of non-glucosidal based 1,3,4-thiadiazoles as SGLT-2 inhibitors.","authors":"Shivani Sharma, Shubham Kumar, Jeena Gupta, Amit Mittal, Navneet Khurana","doi":"10.1080/17568919.2025.2463869","DOIUrl":"https://doi.org/10.1080/17568919.2025.2463869","url":null,"abstract":"Aim: Type-2 diabetes mellitus (T2DM) is a major metabolic disorder needing insulin-independent treatments; this study developed Schiff base 1,3,4-thiadiazole as Sodium Glucose Co-transporters 2 (SGLT2) inhibitors.Materials and methods: The target compounds were synthesized followed by docking studies, in vitro and in vivo analysis.Results: In vitro assay revealed SSS 6 and SSS 2 exhibited high SGLT2 inhibition activity i.e. 78.57% ± 2.8 and 74.60% ± 1.12 compared to dapagliflozin (93.65% ± 4.48) at same dosage in enzyme inhibition assays. In vivo results reveals that SSS 2 significantly improved excretion of urinary glucose (854 ± 46.51 mg/body weight) as compared to dapagliflozin (775 ± 32.68 mg/body weight. SSS 6 and SSS 2 significantly decreased blood glucose levels (137 ± 4.89 mg/dL and 183 ± 15.07 mg/dL) relative to dapagliflozin (158 ± 15.9 mg/dL).Conclusion: Compounds SSS 6 and SSS 2 emerge as a potential candidates for further investigation as SGLT2 inhibitors for treating T2DM.","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"1-15"},"PeriodicalIF":3.2,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in PROTAC-based therapies for neurodegenerative diseases.

IF 3.2 4区医学

Future medicinal chemistry Pub Date : 2025-02-11 DOI: 10.1080/17568919.2025.2463310

Deyuan Kong, Liying Meng, Pengfei Lin, Guanzhao Wu

{"title":"Advancements in PROTAC-based therapies for neurodegenerative diseases.","authors":"Deyuan Kong, Liying Meng, Pengfei Lin, Guanzhao Wu","doi":"10.1080/17568919.2025.2463310","DOIUrl":"https://doi.org/10.1080/17568919.2025.2463310","url":null,"abstract":"Neurodegenerative diseases are characterized by impairments in movement and cognitive functions. These disorders are frequently associated with the accumulation of misfolded protein aggregates, which present significant challenges for treatment with conventional small-molecule inhibitors. While FDA-approved amyloid-beta-directed antibodies, such as Lecanemab, have recently shown clinical success in modifying disease progression, there are currently no treatments capable of curing neurodegenerative diseases. Emerging technologies like proteolysis-targeting chimeras (PROTACs) offer additional promise by targeting disease-causing proteins for degradation, potentially opening new therapeutic avenues. Recent experiments have demonstrated that PROTACs can specifically target and degrade pathogenic proteins associated with neurodegenerative diseases, thereby offering potential therapeutic avenues. This review discusses the latest advances in employing PROTACs for treating neurodegenerative diseases and delves into the associated challenges and opportunities. Our goal is to provide researchers in drug development with new insights on creating novel PROTACs for therapeutic applications.","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"1-15"},"PeriodicalIF":3.2,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EGFR molecular degraders: preclinical successes and the road ahead.

IF 3.2 4区医学

Future medicinal chemistry Pub Date : 2025-02-10 DOI: 10.1080/17568919.2025.2463871

Naveen Chand Rallabandi, Dayanand Panpatil, Digvijay Gahtory, Umashanker Navik, Raj Kumar

引用次数: 0

How does machine learning augment alchemical binding free energy calculations?

IF 3.2 4区医学

Future medicinal chemistry Pub Date : 2025-02-08 DOI: 10.1080/17568919.2025.2463870

Ingo Muegge, Yunhui Ge

引用次数: 0

Applications of carbon-silicon bioisosterism in drug design and development.

IF 3.2 4区医学

Future medicinal chemistry Pub Date : 2025-02-07 DOI: 10.1080/17568919.2025.2463883

Jean Fotie

引用次数: 0

Refinement of MEK inhibitors.

IF 3.2 4区医学

Future medicinal chemistry Pub Date : 2025-02-05 DOI: 10.1080/17568919.2025.2463311

Ankit Kumar Singh, Adarsh Kumar, Harshwardhan Singh, Amita Verma, Pradeep Kumar

引用次数: 0

The versatility of phenothiazines as an anticancer drug scaffold. 吩噻嗪作为抗癌药物支架的多功能性。

IF 3.2 4区医学

Future medicinal chemistry Pub Date : 2025-02-01 Epub Date: 2025-01-19 DOI: 10.1080/17568919.2025.2453417

Arun Kumar, Deepak Kumar

引用次数: 0

Pharmaceutical technological trends containing flavonoids: a patent review. 含黄酮类化合物的制药技术趋势：专利回顾。

IF 3.2 4区医学

Future medicinal chemistry Pub Date : 2025-02-01 Epub Date: 2025-01-21 DOI: 10.1080/17568919.2025.2453408

Ana Maria Santos Oliveira, Anamaria Mendonça Santos, José Adão Carvalho Nascimento Júnior, Cláudio Carvalho Santana Júnior, João Rafael Lisboa Rego Brito, Jussara Secundo Dos Santos, Saravanan Shanmugam, Paula Dos Passos Menezes, Luiza Abrahão Frank, Mairim Russo Serafini

{"title":"Pharmaceutical technological trends containing flavonoids: a patent review.","authors":"Ana Maria Santos Oliveira, Anamaria Mendonça Santos, José Adão Carvalho Nascimento Júnior, Cláudio Carvalho Santana Júnior, João Rafael Lisboa Rego Brito, Jussara Secundo Dos Santos, Saravanan Shanmugam, Paula Dos Passos Menezes, Luiza Abrahão Frank, Mairim Russo Serafini","doi":"10.1080/17568919.2025.2453408","DOIUrl":"10.1080/17568919.2025.2453408","url":null,"abstract":"Flavonoids such as silibinin, hesperetin, and phloretin exhibit well-documented biological activities, including anti-inflammatory, cytoprotective, anticarcinogenic, and antioxidant effects. However, their clinical application remains limited due to challenges such as poor aqueous solubility, low bioavailability, and restricted intestinal absorption, which can significantly reduce their pharmacological efficacy. This review analyzed patents related to innovative pharmaceutical technologies for flavonoids. The analysis used databases from the World Intellectual Property Organization and the European Patent Office. Following a comprehensive screening process, 38 patents were selected for detailed examination. These patents highlighted numerous studies on novel formulations, characterizations, and proprietary conditions. This review highlights technologies, such as nanocapsules, nanoemulsions, solid dispersions, phospholipid carriers, inclusion complexes, microemulsions, and other advanced systems, which enhance bioactive molecules' water solubility and stability. Consequently, these technologies improve permeability and absorption through the intended administration route, demonstrating the potential of flavonoids as promising candidates for various treatments, particularly when integrated into pharmaceutical technologies.","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"363-379"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0